CA2878867C - Dosing regimen for janus kinase (jak) inhibitors - Google Patents

Dosing regimen for janus kinase (jak) inhibitors Download PDF

Info

Publication number
CA2878867C
CA2878867C CA2878867A CA2878867A CA2878867C CA 2878867 C CA2878867 C CA 2878867C CA 2878867 A CA2878867 A CA 2878867A CA 2878867 A CA2878867 A CA 2878867A CA 2878867 C CA2878867 C CA 2878867C
Authority
CA
Canada
Prior art keywords
dose
ring
administration
compound
day
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2878867A
Other languages
English (en)
French (fr)
Other versions
CA2878867A1 (en
Inventor
Andrea J. GONZALES
Sallie B. COSGROVE
Phyllis B. MALPAS
Michael Rolf STEGEMANN
Wendy Turner COLLARD
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zoetis Services LLC
Original Assignee
Zoetis Services LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48901189&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2878867(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Zoetis Services LLC filed Critical Zoetis Services LLC
Publication of CA2878867A1 publication Critical patent/CA2878867A1/en
Application granted granted Critical
Publication of CA2878867C publication Critical patent/CA2878867C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
CA2878867A 2012-07-20 2013-07-18 Dosing regimen for janus kinase (jak) inhibitors Active CA2878867C (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261674289P 2012-07-20 2012-07-20
US61/674,289 2012-07-20
US201361815803P 2013-04-25 2013-04-25
US61/815,803 2013-04-25
PCT/US2013/051015 WO2014015107A1 (en) 2012-07-20 2013-07-18 Dosing regimen for janus kinase (jak) inhibitors

Publications (2)

Publication Number Publication Date
CA2878867A1 CA2878867A1 (en) 2014-01-23
CA2878867C true CA2878867C (en) 2018-01-09

Family

ID=48901189

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2878867A Active CA2878867C (en) 2012-07-20 2013-07-18 Dosing regimen for janus kinase (jak) inhibitors

Country Status (25)

Country Link
US (1) US9522151B2 (enExample)
EP (1) EP2874630B1 (enExample)
JP (2) JP6022063B2 (enExample)
KR (2) KR20170034949A (enExample)
CN (2) CN108354938A (enExample)
AU (1) AU2013292547B2 (enExample)
BR (1) BR112015000808A2 (enExample)
CA (1) CA2878867C (enExample)
CY (1) CY1121436T1 (enExample)
DK (1) DK2874630T3 (enExample)
ES (1) ES2707627T3 (enExample)
HK (2) HK1209314A1 (enExample)
HR (1) HRP20182088T1 (enExample)
HU (1) HUE042771T2 (enExample)
IN (1) IN2015DN00370A (enExample)
LT (1) LT2874630T (enExample)
MX (1) MX360857B (enExample)
NZ (1) NZ703152A (enExample)
PL (1) PL2874630T3 (enExample)
PT (1) PT2874630T (enExample)
RS (1) RS58242B1 (enExample)
SI (1) SI2874630T1 (enExample)
SM (1) SMT201900044T1 (enExample)
WO (1) WO2014015107A1 (enExample)
ZA (1) ZA201500134B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4327812A4 (en) * 2021-04-22 2025-01-15 Shenzhen Chipscreen Biosciences Co., Ltd. PHARMACEUTICAL COMPOSITION CONTAINING A SELECTIVE JAK3/JAK1/TBK1 INHIBITOR AND ITS MEDICAL USE

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA027879B1 (ru) 2013-02-22 2017-09-29 Пфайзер Инк. ПРОИЗВОДНЫЕ ПИРРОЛО[2,3-d]ПИРИМИДИНА В КАЧЕСТВЕ ИНГИБИТОРОВ ЯНУС-РОДСТВЕННЫХ КИНАЗ (JAK)
WO2016024185A1 (en) 2014-08-12 2016-02-18 Pfizer Inc. Pyrrolo[2,3-d]pyrimidine derivatives useful for inhibiting janus kinase
CN116270646A (zh) 2015-10-16 2023-06-23 艾伯维公司 制备咪唑并[1,2-a]吡咯并[2,3-e]吡嗪类化合物及其固态形式的方法
US10550126B2 (en) 2015-10-16 2020-02-04 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-A]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US12365689B2 (en) 2015-10-16 2025-07-22 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US11780848B2 (en) 2015-10-16 2023-10-10 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1- carboxamide and solid state forms thereof
US11365198B2 (en) 2015-10-16 2022-06-21 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US10973913B2 (en) 2016-02-16 2021-04-13 Washington University JAK inhibitors and uses thereof
CN107098908B (zh) 2016-02-23 2021-01-08 欣凯医药科技(上海)有限公司 一种吡咯并嘧啶类化合物的制备方法和应用
KR102195348B1 (ko) 2018-11-15 2020-12-24 에이치케이이노엔 주식회사 단백질 키나제 억제제로서의 신규 화합물 및 이를 포함하는 약제학적 조성물
DK3915989T3 (da) * 2019-01-30 2023-09-18 Felicamed Biotechnology Co Ltd Jak inhibitor and preparation method therefor
US11992490B2 (en) 2019-10-16 2024-05-28 Incyte Corporation Use of JAK1 inhibitors for the treatment of cutaneous lupus erythematosus and Lichen planus (LP)
WO2022133420A1 (en) 2020-12-18 2022-06-23 Boehringer Ingelheim Animal Health USA Inc. Boron containing pyrazole compounds, compositions comprising them, methods and uses thereof
CA3303899A1 (en) * 2021-03-16 2026-05-13 Hk Inno.N Corporation Novel salts of heterocyclic compound as protein kinase inhibitor and uses thereof
WO2024259429A2 (en) * 2023-06-16 2024-12-19 The University Of Chicago Methods and compositions for pharmaceutically relevant interactions

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU3951899A (en) 1998-06-19 2000-01-05 Pfizer Products Inc. Pyrrolo(2,3-d)pyrimidine compounds
RS53382B (sr) 2008-08-20 2014-10-31 Zoetis Llc Jedinjenja pirol [2,3-d]pirimidina

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4327812A4 (en) * 2021-04-22 2025-01-15 Shenzhen Chipscreen Biosciences Co., Ltd. PHARMACEUTICAL COMPOSITION CONTAINING A SELECTIVE JAK3/JAK1/TBK1 INHIBITOR AND ITS MEDICAL USE

Also Published As

Publication number Publication date
WO2014015107A1 (en) 2014-01-23
ES2707627T3 (es) 2019-04-04
MX2015000871A (es) 2015-05-07
BR112015000808A2 (pt) 2017-06-27
CN104470525A (zh) 2015-03-25
HRP20182088T1 (hr) 2019-02-08
RS58242B1 (sr) 2019-03-29
HK1252083A1 (zh) 2019-05-17
HK1209314A1 (en) 2016-04-01
EP2874630B1 (en) 2018-12-05
JP6022063B2 (ja) 2016-11-09
KR20170034949A (ko) 2017-03-29
IN2015DN00370A (enExample) 2015-06-12
SMT201900044T1 (it) 2019-02-28
CY1121436T1 (el) 2020-05-29
PT2874630T (pt) 2019-01-31
LT2874630T (lt) 2019-02-11
CN108354938A (zh) 2018-08-03
US20150126535A1 (en) 2015-05-07
EP2874630A1 (en) 2015-05-27
AU2013292547A1 (en) 2015-01-22
SI2874630T1 (sl) 2019-04-30
KR20150028299A (ko) 2015-03-13
JP2017019816A (ja) 2017-01-26
NZ703152A (en) 2016-03-31
US9522151B2 (en) 2016-12-20
CA2878867A1 (en) 2014-01-23
HUE042771T2 (hu) 2019-07-29
PL2874630T3 (pl) 2019-04-30
JP2015522620A (ja) 2015-08-06
ZA201500134B (en) 2016-08-31
AU2013292547B2 (en) 2017-05-04
DK2874630T3 (en) 2019-01-28
MX360857B (es) 2018-11-20

Similar Documents

Publication Publication Date Title
AU2013292547B2 (en) Dosing regimen for Janus Kinase (JAK) inhibitors
Coffey et al. The novel kinase inhibitor PRT062070 (Cerdulatinib) demonstrates efficacy in models of autoimmunity and B-cell cancer
US11318151B2 (en) Compound pharmaceutical composition for treating skin inflammatory diseases
JP6815728B2 (ja) 新規の使用
US20190314382A1 (en) Compounds and pharmaceutical compositions thereof for the treatment of inflammatory diseases
AU2020347561B2 (en) Treatment of hidradenitis with JAK inhibitors
Morini et al. Development of an oral treatment that rescues gait ataxia and retinal degeneration in a phenotypic mouse model of familial dysautonomia
ES3059530T3 (en) Jak1 pathway inhibitors for the treatment of prurigo nodularis
CN119112900A (zh) 抗胶质母细胞瘤的药物组合物及其应用
CN118984704A (zh) 治疗卵巢癌的药物组合和方法
US20230293544A1 (en) Methods, dosage regimens, and compositions for treating hidradenitis
US20250002492A1 (en) Compositions of folate absorption inhibitors and methods thereof
US20230416244A1 (en) Imidazoquinoline compound having anti-inflammatory, antifugal, antiparasitic, and anticancer activity
WO2017160813A1 (en) Compositions and methods for treating compulsive-like behavior in a subject
WO2026102437A1 (en) Methods of treating fragile x syndrome using pde4 inhibitors
HK40115079A (en) Methods, dosage regimens, and compositions for treating hidradenitis
TH94741B (th) อนุพันธ์ไพราโซโล-ควินาโซลีนที่ถูกแทนที่, กระบวนการสำหรับการเตรียมของพวกมันและการใช้งานของพวกมันเป็นสารยับยั้งไคเนส
TH101974A (th) อนุพันธ์ไพราโซโล-ควินาโซลีนที่ถูกแทนที่, กระบวนการสำหรับการเตรียมของพวกมันและการใช้งานของพวกมันเป็นสารยับยั้งไคเนส

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20150109

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 12TH ANNIV.) - STANDARD

Year of fee payment: 12

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250612

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250612

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 13TH ANNIV.) - STANDARD

Year of fee payment: 13

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20260608

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20260608